Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region - Differential Diagnosis and Therapeutic Implications

Sep 21, 2026

Upload by Logic

The chromosomal region 12q13-15 harbors multiple oncogenes, including MDM2, CDK4, STAT6, DDIT3, and GLI1, driving the pathogenesis of diverse mesenchymal tumors. MDM2 and CDK4 amplifications occur across both mesenchymal and nonmesenchymal neoplasms, so genetic findings require correlation with clinical, radiologic, morphologic, and immunohistochemical features for definitive diagnosis. Coamplification of MDM2 with CDK4 and GLI1 highlights potential targeted therapy. MDM2/CDK4 alterations may also support development of inhibitors beyond mesenchymal settings.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages21

Reading Time53 min

AccessFree to download

Introduction

Clinical and diagnostic considerations

Genetic alterations in 12q13-15

Diagnostic role of MDM2/CDK4/GLI1

Integrating molecular with pathology findings

Therapeutic implications

Targeting MDM2/CDK4 pathways

cancers Review Soft Tissue Sarcomas with Chromosomal Alterationsin the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications Javier Lavernia 1, Reyes Claramunt 2, Ignacio Romero 1,*, Jos² Antonio Lâpez-Guerrero 2, Antonio Llombart-Bosch 3 and Isidro Machado 3,4,5,6, * Citation: Lavernia, J.; Claramunt, R.; Romero, I.; López-Guerrero, J.A.; Llombart-Bosch, A.; Machado, I. Soft Tissue Sarcomas with Chromosomal Alterations in the 12q13-15 Region: Differential Diagnosis and Therapeutic Implications. Cancers 2024, 16, 432. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cancers16020432](10.3390/cancers16020432) Academic Editor: Armita Bahrami Received: 16 December 2023 Revised: 13 January 2024 Accepted: 16 January 2024 Published: 19 January 2024 Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) . 1 Oncology Unit, Instituto Valenciano de Oncolog½a, 46009 Valencia, Spain; jlavernia@ﬁ[vo.org](vo.org) 2 Laboratory of Molecular Biology, Instituto Valenciano de Oncolog½a, 46009 Valencia, Spain; rclaramunt@ﬁ[vo.org](vo.org) (R.C.); jalopez@ﬁ[vo.org](vo.org) (J.A.L.-G.) 3 Pathology Department, University of Valencia, 46010 Valencia, Spain; [antonio.llombart@uv.es](antonio.llombart@uv.es) 4 Pathology Department, Instituto Valenciano de Oncolog½a, 46010 Valencia, Spain 5 CIBERONC Cancer, 28029 Madrid, Spain 6 Patologika Laboratory, Hospital Quiron-Salud, 46010 Valencia, Spain * Correspondence: iromero@ﬁ[vo.org](vo.org) (I.R.); [isidro.machado@uv.es](isidro.machado@uv.es) (I.M.) Simple Summary: The chromosomal region 12q13-15 is rich in oncogenes (MDM2, CDK4, STAT6, DDIT3, and GLI1). Ampliﬁcation of MDM2 and CDK4 genes can be detected in various mesenchymaland nonmesenchymal neoplasms. Therefore, gene ampliﬁcation alone is not entirely speciﬁc for making a deﬁnitive diagnosis and requires the integration of clinical, radiological, morphological, and immunohistochemical ﬁndings. Despite the diagnostic implications that the overlap of genetic alterations in neoplasms with changes in genes within the 12q13-15 region could create, the discovery of coampliﬁcations of MDM2 with CDK4 and GLI1 offers new therapeutic targets in neoplasms with MDM2/CDK4 ampliﬁcation. In this review, we delve into the diagnosis and therapeutic implications of neoplasms with genetic alterations involving the chromosomal region 12q13-15, mainly MDM2, CDK4, and GLI1 . Abstract: The chromosomal region 12q13-15 is rich in oncogenes and contains several genes involved in the pathogenesis of various mesenchymal neoplasms. Notable genes in this region include MDM2, CDK4, STAT6, DDIT3, and GLI1 . Ampliﬁcation of MDM2 and CDK4 genes can be detected in various mesenchymal and nonmesenchymal neoplasms. Therefore, gene ampliﬁcation alone is not entirely speciﬁc for making a deﬁnitive diagnosis and requires the integration of clinical, radiological, morphological, and immunohistochemical ﬁndings. Neoplasms with GLI1 alterations may exhibit either GLI1 rearrangements or ampliﬁcations of this gene. Despite the diagnostic implications that the overlap of genetic alterations in neoplasms with changes in genes within the 12q13-15 region could create, the discovery of coampliﬁcations of MDM2 with CDK4 and GLI1 offers new therapeutic targets in neoplasms with MDM2/CDK4 ampliﬁcation. Lastly, it is worth noting that MDM2 or CDK4 ampliﬁcation is not exclusive to mesenchymal neoplasms; this genetic alteration has also been observed in other epithelial neoplasms or melanomas. This suggests the potential use of MDM2 or CDK4 inhibitors in neoplasms where alterations in these genes do not aid the pathological diagnosis but ma

FAQs

Why is MDM2/CDK4 amplification not sufficient for a definitive diagnosis of soft tissue sarcomas?

MDM2 and CDK4 amplifications can be detected in various mesenchymal and nonmesenchymal neoplasms. A definitive diagnosis requires integrating clinical, radiologic, morphologic, and immunohistochemical findings.

Which oncogenes are highlighted in the 12q13-15 chromosomal region?

The review emphasizes that 12q13-15 is rich in oncogenes, including MDM2, CDK4, STAT6, DDIT3, and GLI1.

What therapeutic implications arise from coamplifications involving MDM2, CDK4, and GLI1?

Discovery of coamplifications of MDM2 with CDK4 and GLI1 suggests new therapeutic targets, especially in tumors showing MDM2/CDK4 amplification. The review also notes that MDM2/CDK4 inhibitors may be relevant even when these alterations do not aid diagnosis.

Sep 21, 2026

Upload by Logic